Hereditary Hemorrhagic Telangiectasia - a literature review
DOI:
https://doi.org/10.12775/JEHS.2024.65.006Keywords
hereditary hemorrhagic telangiectasia, HHT, Rendu-Osler-Weber disease, Osler-Weber-Rendu syndrome, ORW disease, telangiectasiaAbstract
Introduction and purpose: Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a rare and complex vascular disorder characterized by abnormal blood vessel formation. It can present significant challenges in diagnosis and management, as it is currently estimated up to 90% of those affected are never diagnosed. Despite its rarity, HHT can carry substantial implications for patients and their families, at times requiring comprehensive medical care and support. This paper aims to provide an in-depth exploration of HHT, encompassing its epidemiology, genetics, clinical manifestations, diagnostic approaches, and current management strategies. Moreover, we hope to point out possible areas in need of future research.
Description of the state knowledge: HHT is an autosomal dominant genetic disorder that affects 1 in 5-10,000 people. Its most prominent symptoms include telangiectasia of skin and mucous membranes, recurrent epistaxis, gastrointestinal bleeding and arteriovenous malformations in vital organs. In the vast majority of cases, it is caused by a mutation in one of the following genes: ENG, ACVRL1, SMAD4; however, mutations in other genes have been described to cause a similar or much the same constellation of symptoms. Treatment options are focused on managing symptoms and improving quality of life, but possible new treatment options are being researched that could change the landscape of HHT management.
Summary: HHT is a severely underdiagnosed disease that has seen a surge of researchers’ interest in recent years. We firmly believe that, combined with plummeting costs of genetic testing and possible new treatment options, means that HHT will become increasingly important in physicians’ everyday practice.
References
French National Institute for Health and Medical Research 2024, Orphanet, accessed 1 January 2024, <https://www.orpha.net/>
Cure HHT 2024, Cure HHT, accessed 1 November 2024, <https://curehht.org/>
Dupuis-Girod, S., Bailly, S., & Plauchu, H. (2010). Hereditary hemorrhagic telangiectasia: from molecular biology to patient care. Journal of Thrombosis and Haemostasis, 8(7), 1447–1456. https://doi.org/10.1111/J.1538-7836.2010.03860.X
Johnson, D. W., Berg, J. N., Baldwin, M. A., Gallione, C. J., Marondel, I., Yoon, S. J., Stenzel, T. T., Speer, M., Pericak-Vance, M. A., Diamond, A., Guttmacher, A. E., Jackson, C. E., Attisano, L., Kucherlapati, R., Porteous, M. E. M., & Marchuk, D. A. (1996). Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nature Genetics, 13(2), 189–195. https://doi.org/10.1038/NG0696-189
McAllister, K. A., Grogg, K. M., Johnson, D. W., Gallione, C. J., Baldwin, M. A., Jackson, C. E., Helmbold, E. A., Markel, D. S., McKinnon, W. C., Murrel, J., McCormick, M. K., Pericak-Vance, M. A., Heutink, P., Oostra, B. A., Haitjema, T., Westerman, C. J. J., Porteous, M. E., Guttmacher, A. E., Letarte, M., & Marchuk, D. A. (1994). Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nature Genetics, 8(4), 345–351. https://doi.org/10.1038/NG1294-345
Gallione, C. J., Repetto, G. M., Legius, E., Rustgi, A. K., Schelley, S. L., Tejpar, S., Mitchell, G., Drouin, É., Westermann, C. J. J., & Marchuk, D. A. (2004). A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet (London, England), 363(9412), 852–859. https://doi.org/10.1016/S0140-6736(04)15732-2
Balachandar, S., Graves, T. J., Shimonty, A., Kerr, K., Kilner, J., Xiao, S., Slade, R., Sroya, M., Alikian, M., Curetean, E., Thomas, E., McConnell, V. P. M., McKee, S., Boardman-Pretty, F., Devereau, A., Fowler, T. A., Caulfield, M. J., Alton, E. W., Ferguson, T., … Shovlin, C. L. (2022). Identification and validation of a novel pathogenic variant in GDF2 (BMP9) responsible for hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations. American Journal of Medical Genetics Part A, 188(3), 959–964. https://doi.org/10.1002/AJMG.A.62584
Bayrak-Toydemir, P., McDonald, J., Akarsu, N., Toydemir, R. M., Calderon, F., Tuncali, T., Tang, W., Miller, F., & Mao, R. (2006). A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. American Journal of Medical Genetics. Part A, 140(20), 2155–2162. https://doi.org/10.1002/AJMG.A.31450
Farhan, A., Yuan, F., Partan, E., & Weiss, C. R. (2022). Clinical manifestations of patients with GDF2 mutations associated with hereditary hemorrhagic telangiectasia type 5. American Journal of Medical Genetics, Part A, 188(1), 199–209. https://doi.org/10.1002/AJMG.A.62522
Hernandez, F., Huether, R., Carter, L., Johnston, T., Thompson, J., Gossage, J. R., Chao, E., & Elliott, A. M. (2015). Mutations in RASA1 and GDF2 identified in patients with clinical features of hereditary hemorrhagic telangiectasia. Human Genome Variation 2015 2:1, 2(1), 1–6. https://doi.org/10.1038/hgv.2015.40
Boon, L. M., Mulliken, J. B., & Vikkula, M. (2005). RASA1: variable phenotype with capillary and arteriovenous malformations. Current Opinion in Genetics & Development, 15(3), 265–269. https://doi.org/10.1016/J.GDE.2005.03.004
Fuchizaki, U., Miyamori, H., Kitagawa, S., Kaneko, S., & Kobayashi, K. (2003). Hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease). Lancet (London, England), 362(9394), 1490–1494. https://doi.org/10.1016/S0140-6736(03)14696-X
Shovlin, C. L., Guttmacher, A. E., Buscarini, E., Faughnan, M. E., Hyland, R. H., Westermann, C. J. J., Kjeldsen, A. D., & Plauchu, H. (2000). Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). American Journal of Medical Genetics, 91(1), 66–67. https://doi.org/10.1002/(SICI)1096-8628(20000306)91:1%3C66::AID-AJMG12%3E3.0.CO;2-P
Faughnan, M. E., Palda, V. A., Garcia-Tsao, G., Geisthoff, U. W., McDonald, J., Proctor, D. D., Spears, J., Brown, D. H., Buscarini, E., Chesnutt, M. S., Cottin, V., Ganguly, A., Gossage, J. R., Guttmacher, A. E., Hyland, R. H., Kennedy, S. J., Korzenik, J., Mager, J. J., Ozanne, A. P., … Zarrabeitia, R. (2011). International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. Journal of Medical Genetics, 48(2), 73–87. https://doi.org/10.1136/JMG.2009.069013
Faughnan, M. E., Mager, J. J., Hetts, S. W., Palda, V. A., Lang-Robertson, K., Buscarini, E., Deslandres, E., Kasthuri, R. S., Lausman, A., Poetker, D., Ratjen, F., Chesnutt, M. S., Clancy, M., Whitehead, K. J., Al-Samkari, H., Chakinala, M., Conrad, M., Cortes, D., Crocione, C., … Zarrabeitia, R. (2020). Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Annals of Internal Medicine, 173(12), 989–1001. https://doi.org/10.7326/M20-1443
Dupuis-Girod, S., Shovlin, C. L., Kjeldsen, A. D., Mager, H. J., Sabba, C., Droege, F., Fargeton, A. E., Fialla, A. D., Gandolfi, S., Hermann, R., Lenato, G. M., Manfredi, G., Post, M. C., Rennie, C., Suppressa, P., Sure, U., Crocione, C., Blom, R., Botella, L. M., … Buscarini, E. (2022). European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)? European Journal of Medical Genetics, 65(10). https://doi.org/10.1016/J.EJMG.2022.104575
Al-Samkari, H., Albitar, H. A., Olitsky, S. E., Clancy, M. S., & Iyer, V. N. (2020). An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia. Haemophilia : The Official Journal of the World Federation of Hemophilia, 26(6), 1038–1045. https://doi.org/10.1111/HAE.14034
Al-Samkari, H., Kasthuri, R. S., Parambil, J. G., Albitar, H. A., Almodallal, Y. A., Vázquez, C., Serra, M. M., Dupuis-Girod, S., Wilsen, C. B., McWilliams, J. P., Fountain, E. H., Gossage, J. R., Weiss, C. R., Latif, M. A., Issachar, A., Mei-Zahav, M., Meek, M. E., Conrad, M., Rodriguez-Lopez, J., … Iyer, V. N. (2021). An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. Haematologica, 106(8), 2161. https://doi.org/10.3324/HAEMATOL.2020.261859
Chen, H., Zhang, Z., Chen, X., Wang, C., Chen, M., Liao, H., Zhu, J., Zheng, Z., & Chen, R. (2023). Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis. Frontiers in Pharmacology, 14, 1089847. https://doi.org/10.3389/FPHAR.2023.1089847/BIBTEX
Dupuis-Girod, S., Rivière, S., Lavigne, C., Fargeton, A. E., Gilbert-Dussardier, B., Grobost, V., Leguy-Seguin, V., Maillard, H., Mohamed, S., Decullier, E., Roux, A., Bernard, L., Saurin, J. C., Saroul, N., Faure, F., Cartier, C., Altwegg, R., Laccourreye, L., Oberti, F., … Chinet, T. (2023). Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial. Journal of Internal Medicine, 294(6), 761–774. https://doi.org/10.1111/JOIM.13714
Dheyauldeen, S., Østertun Geirdal, A., Osnes, T., Vartdal, L. S., & Dollner, R. (2012). Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: Effectiveness of an injection protocol based on the vascular anatomy of the nose. The Laryngoscope, 122(6), 1210–1214. https://doi.org/10.1002/LARY.23303
Steineger, J., Geirdal, A. Ø., Osnes, T., Heimdal, K. R., & Dheyauldeen, S. (2020). Intranasal bevacizumab injections improve quality of life in HHT patients. The Laryngoscope, 130(5), E284–E288. https://doi.org/10.1002/LARY.28179
Dupuis-Girod, S., Ambrun, A., Decullier, E., Fargeton, A. E., Roux, A., Bréant, V., Colombet, B., Rivière, S., Cartier, C., Lacombe, P., Chinet, T., Blivet, S., Blondel, J. H., Gilbert-Dussardier, B., Dufour, X., Michel, J., Harle, J. R., Dessi, P., & Faure, F. (2016). Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial. JAMA, 316(9), 934–942. https://doi.org/10.1001/JAMA.2016.11387
Whitehead, K. J., Sautter, N. B., McWilliams, J. P., Chakinala, M. M., Merlo, C. A., Johnson, M. H., James, M., Everett, E. M., Clancy, M. S., Faughnan, M. E., Oh, S. P., Olitsky, S. E., Pyeritz, R. E., & Gossage, J. R. (2016). Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial. JAMA, 316(9), 943–951. https://doi.org/10.1001/JAMA.2016.11724
Canzonieri, C., Centenara, L., Ornati, F., Pagella, F., Matti, E., Alvisi, C., Danesino, C., Perego, M., & Olivieri, C. (2014). Endoscopic evaluation of gastrointestinal tract in patients with hereditary hemorrhagic telangiectasia and correlation with their genotypes. Genetics in Medicine, 16(1), 3–10. https://doi.org/10.1038/gim.2013.62
Shovlin, C. L., Buscarini, E., Sabbà, C., Mager, H. J., Kjeldsen, A. D., Pagella, F., Sure, U., Ugolini, S., Torring, P. M., Suppressa, P., Rennie, C., Post, M. C., Patel, M. C., Nielsen, T. H., Manfredi, G., Lenato, G. M., Lefroy, D., Kariholu, U., Jones, B., … Dupuis-Girod, S. (2022). The European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care. European Journal of Medical Genetics, 65(1), 104370. https://doi.org/10.1016/J.EJMG.2021.104370
Shovlin, C. L., Millar, C. M., Droege, F., Kjeldsen, A., Manfredi, G., Suppressa, P., Ugolini, S., Coote, N., Fialla, A. D., Geisthoff, U., Lenato, G. M., Mager, H. J., Pagella, F., Post, M. C., Sabbà, C., Sure, U., Torring, P. M., Dupuis-Girod, S., & Buscarini, E. (2019). Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia. Orphanet Journal of Rare Diseases, 14(1). https://doi.org/10.1186/S13023-019-1179-1
Eker, O. F., Boccardi, E., Sure, U., Patel, M. C., Alicante, S., Alsafi, A., Coote, N., Droege, F., Dupuis, O., Fialla, A. D., Jones, B., Kariholu, U., Kjeldsen, A. D., Lefroy, D., Lenato, G. M., Mager, H. J., Manfredi, G., Nielsen, T. H., Pagella, F., … Shovlin, C. L. (2020). European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT). Orphanet Journal of Rare Diseases, 15(1). https://doi.org/10.1186/S13023-020-01386-9
Buscarini, E., Plauchu, H., Garcia Tsao, G., White, R. I., Sabbà, C., Miller, F., Saurin, J. C., Pelage, J. P., Lesca, G., Marion, M. J., Perna, A., & Faughnan, M. E. (2006). Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations. Liver International : Official Journal of the International Association for the Study of the Liver, 26(9), 1040–1046. https://doi.org/10.1111/J.1478-3231.2006.01340.X
Shovlin, C. L., Buscarini, E., Kjeldsen, A. D., Mager, H. J., Sabba, C., Droege, F., Geisthoff, U., Ugolini, S., & Dupuis-Girod, S. (2018). European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT). Orphanet Journal of Rare Diseases, 13(1). https://doi.org/10.1186/S13023-018-0850-2
Bari, O., & Cohen, P. R. (2017). Hereditary hemorrhagic telangiectasia and pregnancy: Potential adverse events and pregnancy outcomes. International Journal of Women’s Health, 9, 373–378. https://doi.org/10.2147/IJWH.S131585
Shovlin, C. L., Sodhi, V., McCarthy, A., Lasjaunias, P., Jackson, J. E., & Sheppard, M. N. (2008). Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): suggested approach for obstetric services. BJOG : An International Journal of Obstetrics and Gynaecology, 115(9), 1108–1115. https://doi.org/10.1111/J.1471-0528.2008.01786.X
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Marcel Stodolak, Aleksandra Krużel, Kamil Kłos, Piotr Sajdak, Justyna Tomasik, Marika Dębik, Łukasz Szydłowski, Klaudia Żurowska, Seweryn Ziajor, Artur Bednarski, Mikołaj Turski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 325
Number of citations: 0
